Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy

[1]  H. Vanderstichele,et al.  How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology , 2020, Neurobiology of Disease.

[2]  V. Baekelandt,et al.  The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies , 2020, Acta Neuropathologica.

[3]  Han-Joon Kim,et al.  Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies , 2019, Journal of movement disorders.

[4]  J. Trojanowski,et al.  Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease , 2019, Neurobiology of Disease.

[5]  J. Attems,et al.  Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies – current issues and future directions , 2019, Journal of neurochemistry.

[6]  W. V. van IJcken,et al.  Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes , 2019, Nature Neuroscience.

[7]  C. Holmes,et al.  Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer’s disease , 2019, Brain : a journal of neurology.

[8]  H. Wood.  Naturally occurring antibodies target Parkinson disease pathology , 2019, Nature Reviews Neurology.

[9]  J. Hoozemans,et al.  Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology , 2019, Acta Neuropathologica.

[10]  Alan J. Thomas,et al.  Dementia with Lewy bodies: an update and outlook , 2019, Molecular Neurodegeneration.

[11]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[12]  W. Poewe,et al.  Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy , 2018, Front. Neurosci..

[13]  J. Cedarbaum,et al.  Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease (S26.001) , 2018 .

[14]  John L. Robinson,et al.  Cellular Milieu Imparts Distinct Pathological α-Synuclein Strains in α-Synucleinopathies , 2018, Nature.

[15]  K. Jellinger.  Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy , 2017, Journal of Alzheimer's disease : JAD.

[16]  Anne K. Braczynski,et al.  Vaccination strategies in tauopathies and synucleinopathies , 2017, Journal of neurochemistry.

[17]  Pei-Ning Wang,et al.  UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease , 2017, Alzheimer's & dementia.

[18]  A. Makky,et al.  Nanomechanical properties of distinct fibrillar polymorphs of the protein α-synuclein , 2016, Scientific Reports.

[19]  M. Grundman,et al.  First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers , 2016, Movement disorders : official journal of the Movement Disorder Society.

[20]  D. Marciani.  A retrospective analysis of the Alzheimer's disease vaccine progress – The critical need for new development strategies , 2016, Journal of neurochemistry.

[21]  P. Mitchell,et al.  Assessment of polygenic effects links primary open-angle glaucoma and age-related macular degeneration , 2016, Scientific Reports.

[22]  R. Melki,et al.  Structural and functional properties of prefibrillar α-synuclein oligomers , 2016, Scientific Reports.

[23]  Seung-Jae Lee,et al.  Mechanism of Anti-α-Synuclein Immunotherapy , 2016, Journal of movement disorders.

[24]  G. Petsko,et al.  Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations , 2015, The Lancet Neurology.

[25]  M. Giugliano,et al.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration , 2015, Nature.

[26]  E. Masliah,et al.  Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy , 2015, Molecular Neurodegeneration.

[27]  D. Berg,et al.  Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson’s Disease: Sources of (Error) Variance in Biomarker Assays , 2014, PloS one.

[28]  E. Masliah,et al.  Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models , 2014, The Journal of Neuroscience.

[29]  M. Farlow,et al.  Immunotherapy for Alzheimer's disease. , 2013, Neurologic clinics.

[30]  E. Masliah,et al.  Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission , 2012, The Journal of Neuroscience.

[31]  E. Masliah,et al.  Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease , 2011, PloS one.

[32]  W. Oertel,et al.  Naturally Occurring Autoantibodies against β-Amyloid: Investigating Their Role in Transgenic Animal and In Vitro Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[33]  J. Yesavage,et al.  Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[34]  Changcai Wang,et al.  Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease , 2007 .

[35]  H. Braak,et al.  Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology , 2006, Neuroscience Letters.

[36]  J. Mallet,et al.  PA700, the regulatory complex of the 26S proteasome, interferes with α‐synuclein assembly , 2005 .

[37]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[38]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[39]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[40]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[41]  S. M. Robinson,et al.  Passage of amyloid β protein antibody across the blood–brain barrier in a mouse model of Alzheimer’s disease , 2002, Peptides.

[42]  V. Uversky,et al.  Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.

[43]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[44]  T. Golde.  Alzheimer's Research & Therapy , 2009 .

[45]  Changcai Wang,et al.  Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. , 2007, Vaccine.

[46]  E. Masliah,et al.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.

[47]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[48]  S. M. Robinson,et al.  Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. , 2002, Peptides.